Pathos AI acquired a majority stake in Belgium-based DeuterOncology to advance DO-2, a deuterated third-generation MET kinase inhibitor identified through Pathos's Foundry AI platform. DO-2 targets MET-altered NSCLC and other solid tumors with a profile designed to reduce the peripheral edema seen in current MET inhibitors. Financial terms were not disclosed.
Key facts
AnnouncedMay 06, 2026
ClosedMay 06, 2026
Deal typeAcquisition/Merger
Therapeutic areaMET-altered NSCLC and other solid tumors
IndicationsMET-altered NSCLC and other solid tumors
Key assetsDO-2 (deuterated third-generation MET kinase inhibitor)
MechanismDeuterated third-generation MET kinase inhibitor (oral) with improved tolerability profile